Advances in Bioresearch
Adv. Biores., Vol 15 (2) March 2024: 155-161

Print ISSN 0976-4585; Online ISSN 2277-1573
Journal's URL:http://www.soeagra.com/abr.html
CODEN: ABRDC3
DOI: 10.15515/abr.0976-4585.15.2.155161

Advances in Bioresearch

REVIEW ARTICLE

Neuroinflammation in Neurodegenerative Diseases: Targeting Pathways for Therapy

[1]Iype Cherian, [2]Harisinh Parmar, [3]Aniket Avhad, [4]Dany John, [5]Abhijit Patil
[1,2]Dept. of Neurology, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India
[3,4]Dept.of Cardiology Kishna Institute of Medical Sciences Krishna Vishwa Vidyapeeth, Karad, Maharashtra
[5]Department of General Medicine Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed to Be University, Karad, Maharashtra

ABSTRACT
One important factor in neurodegenerative illnesses is neuroinflammation, which represents a complex interaction between immune-mediated responses in the central nervous system (CNS). Neuronal damage is exacerbated in diseases such as Parkinson's, Alzheimer's, and multiple sclerosis due to the dysregulated activation of microglia and astrocytes that sustain a persistent inflammatory state. The many ways that astrocyte dysfunction, cytokine signalling, and microglial activation contribute to neuroinflammation are thoroughly examined in this study. Comprehending these complex processes reveals possible targets for therapy to reduce neuroinflammatory reactions. Prospective paths for therapeutic treatments are revealed by investigating immunomodulatory medicines, anti-inflammatory medications, and therapies that target particular inflammatory cascades. Treatments that change the condition may be possible if they target glial homeostasis, cytokine signalling regulation, and microglial phenotyping. However, the conversion of preclinical discoveries into clinically useful treatments is hampered by issues including patient heterogeneity, specificity of interventions, and blood-brain barrier penetration. This review highlights the importance of tailored therapy methods in reducing neuronal damage and maintaining cognitive function by compiling the most recent data on neuroinflammation pathways in neurodegenerative illnesses.
***Keywords**: Neuroinflammation, Neurodegenerative Diseases, Microglia, Cytokine Signaling, Therapeutic Strategies*

Received 24.11.2023 Revised 02.12.2023 Accepted 21.03.2024

How to cite this article:
Iype C, Harisinh P, Aniket A, Dany J, Abhijit P. Neuroinflammation in Neurodegenerative Diseases: Targeting Pathways for Therapy. Adv. Biores., Vol 15 (2) March 2024:155-161

INTRODUCTION

A range of crippling disorders known as neurodegenerative diseases are defined by the gradual death of neurons, which results in cognitive and physical impairment. Notable instances include illnesses that impact millions of people globally, such as multiple sclerosis (MS), Parkinson's, Alzheimer's, and Huntington's. Although the causes of various disorders differ, new research has identified neuroinflammation as a common factor.[1] Neuroinflammation is now understood to be a key factor in the pathophysiology of neurodegenerative illnesses, having previously been thought of as only a subsequent reaction to neuronal damage. It entails a complicated interaction between invading peripheral immune cells and resident immune cells of the central nervous system (CNS), including astrocytes and microglia. Pro-inflammatory cytokines, chemokines, and other mediators are released during this inflammatory response, which sustains a persistent condition of neuroinflammation [2]. One of the defining characteristics of neuroinflammation in neurodegenerative illnesses is the activation of microglia, the central nervous system's main immune cells [3]. Microglia shift morphologically and enter a reactive state in response to pathogenic stimuli, which causes them to release a series of inflammatory mediators. Depending on the circumstances and length of activation, these activated microglia may display both neuroprotective and neurotoxic properties [4].

[5] Astrocytes, which are often regarded as supporting cells, work in tandem with microglia to modulate neuroinflammatory responses. Astrogliosis is the term for the process that reactive astrocytes go through in response to inflammatory stimuli or damage to their neurons. Through the production of cytokines,

chemokines, and neurotoxic chemicals, this metamorphosis entails morphological and functional alterations that further amplify neuroinflammation [6].

A self-sustaining cycle of neuroinflammation is produced by the complex interactions between various cell types and signalling molecules, which greatly contributes to the degeneration of neurons and the advancement of illness [7]. Increased amounts of pro-inflammatory cytokines, such as TNF-α and interleukins (IL-1β, IL-6) and TNF-α, disturb the homeostasis of neurons and intensify neuroinflammation, creating an unfavourable environment for neurons [8].

Moreover, a growing body of research indicates that neuroinflammation actively participates in the pathophysiology of neurodegenerative illnesses rather than being a passive result [9]. Neuronal dysfunction and death are the results of chronic neuroinflammation, which is defined by immune cell activation that persists over time and the continuous production of inflammatory mediators. This feeds back into a vicious loop, escalating neurodegeneration and neuroinflammation [10].

Determining the best treatment strategies requires an understanding of the complex interactions between neuroinflammation and neurodegeneration. One potential approach to treating diseases is to target certain immune responses or inflammatory pathways [11]. Potential treatment approaches to stop or reduce the course of neurodegenerative disorders include methods to modulate microglial activation, regulate cytokine signalling, or restore glial homeostasis [12].

Finally, it can be said that neuroinflammation plays a significant role in the pathophysiology of a number of neurodegenerative illnesses. Determining the precise therapeutic targets within these inflammatory pathways and clarifying the underlying processes offer great potential for creating efficient therapies to reduce neuronal damage and maintain motor and cognitive function in those who are impacted.

The Function of Activation of Microglia in Neuroinflammation

[1] The central nervous system's (CNS) resident immune cells, called microglia, are essential for monitoring and reacting to pathological alterations in the brain. Microglia, which have historically been thought of as the brain's "macrophages," are crucial for immunological surveillance, synaptic pruning, and CNS homeostasis [2]. On the other hand, neurodegenerative disorders' development and progression are linked to their dysregulated activation.

Neuroinflammation is closely associated with microglial activation, which is a complex process [3]. When microglia come into contact with pathogenic stimuli, they change from a ramified, surveilling condition to an activated, amoeboid shape [4]. These stimuli can include misfolded proteins, neuronal injury, or inflammatory signals. This activation sets off a dynamic reaction that includes a range of functional alterations, including the production of different inflammatory mediators and phagocytosis.

[5] The paradox of microglial activation indicates that it has a dual function in both neurodegeneration and neuroinflammation. In the past, microglial activation was thought to be a defensive mechanism meant to remove pathogens and debris, which would aid in tissue regeneration and neuronal survival [6]. Prolonged or excessive activation, however, has the potential to tip the scales in favour of a negative phenotype that is marked by the production of reactive oxygen species (ROS), chemokines, and pro-inflammatory cytokines [7].

In neurodegenerative disorders, microglia are activated in a context-dependent and multifactorial manner [8]. For example, microglia with Alzheimer's disease (AD) have a changed phenotype called "dystrophic" microglia, which is characterised by a decreased capacity for phagocytic activity and an inflammatory profile that intensifies damage to neurons [9]. On the other hand, microglial activation in Parkinson's disease (PD) may help remove α-synuclein aggregates but may potentially prolong neuroinflammation and cause dopaminergic neuronal death [10].

[11] The complicated interplay between activated microglia's neuroprotective and neurotoxic properties highlights the intricacy of their involvement in neuroinflammation. According to certain research, in neurodegenerative settings, polarising microglia towards an anti-inflammatory phenotype may provide neuroprotection [12]. In order to lessen neuroinflammation and neuronal injury, this change entails encouraging the release of anti-inflammatory cytokines (such as IL-4 and IL-10) and improving phagocytic clearance of harmful protein aggregates.

Furthermore, the neuroinflammatory milieu is greatly influenced by the communication that occurs between microglia and other CNS cells, including astrocytes and neurons [13]. For example, interactions between microglia and astrocytes can intensify inflammatory reactions, which can set off a series of events that worsen neurodegeneration [14].

[15] There is potential in the developing field of microglial regulation as a therapeutic strategy for neurodegenerative disorders. The goal of strategies that target microglial activation is to maximise their positive effects while reducing their negative ones [16]. Small molecule inhibitors, immunomodulatory

strategies, and innovative immunotherapies are being investigated to regulate microglial activation states and reroute their activity towards a neuroprotective phenotype.
Essentially, microglial activation has a complicated, context-dependent function in neuroinflammation and is essential to the pathophysiology of neurodegenerative disorders. Comprehending the intricate equilibrium between advantageous and disadvantageous facets of microglial activation is imperative in the development of focused therapies designed to optimise their neuroprotective capabilities and mitigate neuroinflammation-induced neuronal impairment.

The Effect of Cytokine Signalling on Neuroinflammation

[1] A broad class of signalling molecules known as cytokines is essential for coordinating the inflammatory response in the central nervous system. Dysregulated cytokine signalling has a major role in the maintenance and aggravation of neuroinflammation in neurodegenerative disorders.
For immune surveillance and homeostasis, the central nervous system (CNS) maintains a fine balance of cytokine signalling [2]. Tumour necrosis factor-alpha (TNF-α) and interleukins (IL) are two examples of the pro-inflammatory cytokines that are dysregulatedly released when this equilibrium is upset, which occurs in neurodegenerative diseases [3].
[4] The development and course of neurodegenerative illnesses are linked to increased concentrations of pro-inflammatory cytokines. For example, elevated IL-1β and IL-6 production by activated microglia and astrocytes in Alzheimer's disease (AD) leads to neuroinflammation, which in turn promotes the formation of amyloid-beta (Aβ) plaques and exacerbates neuronal damage [5].
Similar to this, dysregulated cytokine signalling, namely increased TNF-α production, causes neuroinflammation and neurodegeneration in Parkinson's disease (PD) by activating microglia and triggering neuronal death [6]. These cytokines are released repeatedly, which feeds neuroinflammation and makes the environment unfavourable for neurons.
[7] Cytokine signalling has an influence on neuroinflammation that goes beyond localised consequences. When peripheral immune cells enter the central nervous system (CNS) in reaction to pathogenic stimuli, they add to the cytokine milieu and exacerbate neuroinflammatory reactions [8]. This intensifies the chain reaction of inflammation, generating a feedback loop that sustains the injury to neurons.
Additionally, cytokines influence systemic inflammatory responses by serving as important mediators in the communication between the central nervous system and the peripheral immune system [9]. In addition to influencing local CNS environments, the dysregulated cytokine profile seen in neurodegenerative illnesses also leads to systemic inflammation, which may exacerbate disease pathology.
[10] Cytokine signalling pathway-targeting strategies are a potentially effective therapeutic strategy for neurodegenerative disorders. By counteracting the effects of pro-inflammatory cytokines, anti-cytokine therapies—such as monoclonal antibodies directed against certain cytokines or their receptors—seek to reduce neuroinflammation [11].
Another strategy is to modify the signalling pathways that produce cytokines or trigger subsequent inflammatory cascades [12]. Targeting important signalling molecules in the cytokine pathways, small molecule inhibitors provide a promising treatment option to reduce neuroinflammatory responses and maintain cell integrity.
[13] The intricate relationship between neuroinflammation and cytokine signalling highlights the intricacy of immune-mediated reactions in neurodegenerative illnesses. Although cytokine signalling pathways are promising targets for medicinal development, precisely modulating these pathways without impairing critical immune activities is still a major issue.
In conclusion, cytokine signalling is essential for the development of neuroinflammation in neurodegenerative illnesses. Comprehending the complexities of cytokine dysregulation and its influence on neuronal well-being is crucial for formulating focused treatment approaches intended to reduce neuroinflammatory reactions and maintain cognitive and motor abilities in those impacted.

Astrocyte Failure in Neuroinflammatory Conditions

[1] Astrocytes, which have long been thought of as supporting cells in the central nervous system (CNS), have a variety of functions, including preserving the health of neurons, controlling synaptic transmission, and influencing the immunological response in the brain. Astrocytes have reactive alterations in neurodegenerative disorders, which greatly increase neuroinflammation.
Astrocytes go through a process called astrogliosis when they come into contact with pathogenic stimuli such protein aggregates or inflammatory signals [2]. This transition is marked by hypertrophy, elevated glial fibrillary acidic protein (GFAP) expression, and modified secretory profiles, among other morphological and functional alterations.

[3] The neuroinflammatory milieu is enhanced by reactive astrocytes, which release a wide range of inflammatory mediators, including as chemokines, cytokines, and neurotoxic compounds [4]. Initially reacting to return equilibrium, these cells might, in the presence of persistent inflammation, take on a deleterious character that prolongs neurodegeneration.

Numerous neurodegenerative illnesses are linked to dysregulated astrocyte activation [5]. Reactive astrocytes envelop amyloid plaques in Alzheimer's disease (AD), generating pro-inflammatory cytokines and chemokines that further exacerbate the neuroinflammatory milieu [6]. This persistent inflammatory response impairs synapse function and worsens brain damage.

Similar to this, astrocyte dysfunction plays a role in the advancement of Parkinson's disease (PD). Inflammatory mediators are released by reactive astrocytes in the substantia nigra, which intensifies neuroinflammation and aids in the death of dopaminergic neurons [7].

[8] Neuroinflammation is further exacerbated by the reciprocal communication that occurs between astrocytes and other CNS cells, especially microglia. Interactions between these cell types control inflammatory responses; active microglia cause and maintain astrocyte reactivity, which feeds back into a cycle that prolongs neuroinflammation [9].

Furthermore, astrocyte dysfunction goes beyond the immediate release of mediators that cause inflammation [10]. Neuronal vulnerability and neurodegeneration are exacerbated by impaired astrocytic support and poor homeostatic activities, such as glutamate clearance, ion buffering, and trophic support to neurons.

Because of the many functions that astrocytes play in preserving CNS homeostasis, therapeutic treatments aimed at astrocyte dysfunction in neurodegenerative disorders continue to be difficult to implement. Approaches to control astrocyte reactivity without sacrificing their vital support roles are being researched [12].

Potential therapeutic agents for astrocyte-mediated neuroinflammation include small compounds that block certain pathways involved in astrocyte activation, such as the NF-κB signalling pathway [13]. Furthermore, as possible treatment options, strategies that aim to improve astrocytic support functions—like increasing glutamate clearance or reinstating neurotrophic support—are being investigated.

[14] In summary, astrocyte function dysregulation plays a major role in the persistence of neuroinflammation in neurodegenerative disorders. Comprehending the intricacies of astrocyte reactivity and its influence on neuronal well-being is imperative for formulating focused treatment approaches that attempt to regulate astrocyte malfunction while maintaining their fundamental support roles, consequently reducing neuroinflammation and minimising neuronal impairment.

Treatment Strategies that Aim for Neuroinflammatory Pathways

The complex relationship between neuroinflammation and the aetiology of neurodegenerative disorders has sparked a great deal of interest in the development of focused treatment therapies meant to alter inflammatory pathways. These methods aim to protect neuronal integrity and reduce neuroinflammatory reactions.

Agents of Immunomodulation:

[2] A family of medications known as immunomodulatory drugs is intended to control immune responses in neurodegenerative illnesses. Reducing the excessive inflammation may be possible by altering the immune system's activity. Targeting immune cells, including peripheral immune cells and microglia, compounds seek to either block harmful immune responses or modify the activation states of these cells [3].

Anti-Inflamatory Medication:

[4] The possibility of anti-inflammatory medications, such as corticosteroids and nonsteroidal anti-inflammatory medicines (NSAIDs), to reduce neuroinflammation has been investigated. By lowering the synthesis of pro-inflammatory mediators including prostaglandins and cytokines, these drugs hope to lessen the CNS's inflammatory cascade [5].

Activation of Microglia as the Target:

[6] Methods that target microglial activation explicitly seek to alter the phenotypic states of these cells. Redirecting microglial activity towards a neuroprotective phenotype is a promising use of small molecule inhibitors or biologics that target important signalling pathways involved in microglial activation, such as the TREM2 pathway or the NLRP3 inflammasome [7].

Changing the Cytokine Signalling Process

[8] The goal of cytokine signalling pathway interventions is to counteract or prevent the effects of pro-inflammatory cytokines. Potential treatments to reduce neuroinflammatory reactions include small molecule inhibitors of cytokine signalling pathways and monoclonal antibodies that target certain cytokines or their receptors [9].

Restoring Glial Homeostasis:

[10] One new treatment strategy is glial homeostasis restoration. Neuroinflammation is countered and neuronal damage is mitigated by strategies that enhance astrocytic support activities, such as boosting glutamate clearance or restoring trophic support to neurons [11].

[12] Complexity of the CNS environment, possible off-target effects, and the requirement for precise control of inflammatory pathways without compromising critical immune functions are some of the hurdles facing the development of these treatment techniques. Furthermore, a major obstacle still exists in the translation of encouraging preclinical results into clinically efficacious treatments.

Clinical Trials and Prospects for the Future:

[13] A number of treatment possibilities that target neuroinflammatory pathways are being tested in clinical settings. Clinical trials are being conducted to evaluate the safety and effectiveness of immunomodulatory medicines, anti-inflammatory medications, and tailored therapies in relation to certain inflammatory cascades [14].

[15] Developing new targets and improving current treatment strategies are key future directions in addressing neuroinflammatory pathways. Personalised therapy therapies catered to individual neurodegenerative disease profiles and patient characteristics may be made possible by precision medicine techniques that take into account individual diversity in immune responses [16].

To summarise, there are several treatment methods that target neuroinflammatory pathways, such as immunomodulation and targeted therapies that try to modify certain inflammatory cascades. Developments in these strategies might lead to the creation of efficient therapies that reduce neuroinflammation, maintain the integrity of neurons, and possibly slow the onset of neurodegenerative illnesses. To turn these tactics into treatments that are clinically feasible, further investigation and clinical validation are necessary.

Obstacles and Prospects for the Future of Neuroinflammation Therapy

[1] Notwithstanding notable progress, a number of obstacles continue to exist in the endeavour to successfully address neuroinflammation in the context of neurodegenerative disease therapy. To fully realise the benefits of therapeutic treatments and open the door for future advancements, it is imperative that these issues are resolved.

Breach of the Blood-Brain Barrier (BBB):

[2] By acting as a selective barrier, the blood-brain barrier controls the flow of chemicals from the circulation into the central nervous system. It also makes it more difficult to successfully target neuroinflammation with therapeutic medicines. Many possible treatments are unable to cross the blood-brain barrier (BBB), which limits their ability to influence CNS neuroinflammatory pathways [3].

Intervention Specificity:

[4] It is still very difficult to target neuroinflammation with precision without impairing vital immune processes. Numerous treatment strategies meant to alter immune responses run the risk of disrupting vital immune surveillance or homeostatic processes, which might have negative consequences [5].

Possible Adverse Reactions:

[6] One worry with the development of neuroinflammation-targeted medicines is the possibility of off-target effects and unforeseen outcomes. Therapeutic safety profiles must be carefully evaluated since modifying immune responses or inflammatory pathways may unintentionally worsen pre-existing CNS diseases or cause systemic adverse effects [7].

Interpreting Preclinical Results:

[8] Although preclinical research has demonstrated potential in modifying neuroinflammatory pathways, it is still difficult to convert these discoveries into practical therapeutic treatments. Strengthening translational research and gaining a deeper knowledge of disease processes are crucial to close the gap between preclinical efficacy and clinical success [9].

Patient Variability:

[10] The appearance, course, and underlying pathophysiology of neurodegenerative disorders show notable variability. It is still a difficult effort to develop targeted medicines that take this variability into account and meet the various demands of patients [11].

Multimodal Methodology:

Because neuroinflammation is so complicated, a one-size-fits-all strategy might not be enough. To acquire the best results, it may be important to combine several therapy modalities or create synergistic methods that target different elements of neuroinflammatory pathways [13].

[14] Addressing these issues and looking for novel approaches are the focal points of future thoughts on neuroinflammation targeting:

Cutting-Edge Medication Delivery Systems:
In order to minimise systemic adverse effects, novel drug delivery technologies, such as nanotechnology-based strategies or creative formulations, seek to improve BBB penetration and targeted delivery of therapeutic agents to certain CNS areas [15].
Methods in Precision Medicine:
Precision medicine's advancements, such as the identification of biomarkers and customised treatment plans, have the potential to optimise therapeutic efficacy while minimising side effects by customising therapies to each patient's unique profile [16].
Combined Therapeutic Approaches:
A complete strategy to more effectively modify neuroinflammatory pathways may be provided by combining treatment modalities in a synergistic manner, such as immunomodulation, anti-inflammatory drugs, and targeted therapies [17].
Conclusively, although addressing neuroinflammation in neurodegenerative disorders poses notable obstacles, continuous investigation and inventive methodologies exhibit potential. Overcoming obstacles including blood-brain barrier penetration, intervention specificity, and patient heterogeneity will open the door to more efficient and customised treatments. Future developments in neuroinflammation-targeted therapeutics are anticipated to be shaped by the integration of sophisticated drug delivery systems, precision medicine techniques, and multi-modal therapy methods. These developments should provide hope for better results for those suffering from these crippling illnesses.

REFERENCES

1. Craft, J. M., Watterson, D. M., & Van Eldik, L. J. (2005). Neuroinflammation: a potential therapeutic target. *Expert Opinion on Therapeutic Targets, 9*(5), 887-900. [DOI: 10.1517/14728222.9.5.887]
2. Skaper, S. D. (2007). The brain as a target for inflammatory processes and neuroprotective strategies. *Annals of the New York Academy of Sciences, 1122*, 23-34. [DOI: 10.1196/annals.1403.002]
3. Jha, M. K., & Suk, K. (2014). Management of glia-mediated neuroinflammation and related patents. *Recent Patents on Inflammation & Allergy Drug Discovery, 8*(2), 118-124. [DOI: 10.2174/1872213x08666140619105915]
4. Baby, N., Patnala, R., Ling, E. A., & Dheen, S. T. (2014). Nanomedicine and its application in treatment of microglia-mediated neuroinflammation. *Current Medicinal Chemistry, 21*(37), 4215-4226. [DOI: 10.2174/09298673216661407161012 58]
5. Stama, M. L., Ślusarczyk, J., Lacivita, E., Kirpotina, L. N., Schepetkin, I. A., Chamera, K., ... & Leopoldo, M. (2017). Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation. *European Journal of Medicinal Chemistry, 141*, 703-720. [DOI: 10.1016/j.ejmech.2017.09.023]
6. Sarkar, S., Mazumder, S., Saha, S. J., & Bandyopadhyay, U. (2016). Management of inflammation by natural polyphenols: A comprehensive mechanistic update. *Current Medicinal Chemistry, 23*(16), 1657-1695. [DOI: 10.2174/09298673236661604181155 40]
7. Crowley, T., Cryan, J. F., Downer, E. J., & O'Leary, O. F. (2016). Inhibiting neuroinflammation: The role and therapeutic potential of GABA in neuro-immune interactions. *Brain, Behavior, and Immunity, 54*, 260-277. [DOI: 10.1016/j.bbi.2016.02.001]
8. Singh, A., Chokriwal, A., Sharma, M. M., Jain, D., Saxena, J., & Stephen, B. J. (2017). Therapeutic role and drug delivery potential of neuroinflammation as a target in neurodegenerative disorders. *ACS Chemical Neuroscience, 8*(8), 1645-1655. [DOI: 10.1021/acschemneuro.7b00144]
9. Schenk, G. J., & de Vries, H. E. (2016). Altered blood-brain barrier transport in neuro-inflammatory disorders. *Drug Discovery Today: Technologies, 20*, 5-11. [DOI: 10.1016/j.ddtec.2016.07.002]
10. Van Eldik, L. J., Thompson, W. L., Ralay Ranaivo, H., Behanna, H. A., & Martin Watterson, D. (2007). Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: Function-based and target-based discovery approaches. *International Review of Neurobiology, 82*, 277-296. [DOI: 10.1016/S0074-7742(07)82015-0]
11. Filiou, M. D., Banati, R. B., & Graeber, M. B. (2017). The 18-kDa translocator protein as a CNS drug target: Finding our way through the neuroinflammation fog. *CNS & Neurological Disorders Drug Targets, 16*(9), 990-999. [DOI: 10.2174/18715273166661710041251 07]
12. Masgrau, R., Guaza, C., Ransohoff, R. M., & Galea, E. (2017). Should we stop saying 'Glia' and 'Neuroinflammation'? *Trends in Molecular Medicine, 23*(6), 486-500. [DOI: 10.1016/j.molmed.2017.04.005]
13. Ma, X. W., Li, J. Z., Zhang, T. T., & Du, G. H. (2014). [Recent development of non-steroidal anti-inflammatory drugs on the neuro-inflammation of Alzheimer's disease]. *Yao Xue Xue Bao, 49*(9), 1211-1217. Chinese. [PMID: 25518320]
14. Ullah, F., Liang, A., Rangel, A., Gyengesi, E., Niedermayer, G., & Münch, G. (2017). High bioavailability curcumin: An anti-inflammatory and neurosupportive bioactive nutrient for neurodegenerative diseases characterized by chronic neuroinflammation. *Archives of Toxicology, 91*(4), 1623-1634. [DOI: 10.1007/s00204-017-1939-4]

15. Centonze, D., Finazzi-Agrò, A., Bernardi, G., & Maccarrone, M. (2007). The endocannabinoid system in targeting inflammatory neurodegenerative diseases. *Trends in Pharmacological Sciences, 28*(4), 180-187. [DOI: 10.1016/j.tips.2007.02.004]
16. Al-Amin, M. M., & Reza, H. M. (2014). Neuroinflammation: Contemporary anti-inflammatory treatment approaches. *Neurosciences (Riyadh), 19*(2), 87-92. [PMID: 24739403]
17. Bastias-Candia, S., Garrido, A. N., Zolezzi, J. M., & Inestrosa, N. C. (2016). Recent advances in neuroinflammation therapeutics: PPARs/LXR as neuroinflammatory modulators. *Current Pharmaceutical Design, 22*(10), 1312-1323. [DOI: 10.2174/1381612822666151223103038]
18. Xu, Z., Wu, J., Zheng, J., Ma, H., Zhang, H., Zhen, X., ... & Zhang, X. (2015). Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors. *International Immunopharmacology, 25*(2), 528-537. [DOI: 10.1016/j.intimp.2015.02.033]
19. Xu, J., Dong, H., Qian, Q., Zhang, X., Wang, Y., Jin, W., & Qian, Y. (2017). Astrocyte-derived CCL2 participates in surgery-induced cognitive dysfunction and neuroinflammation via evoking microglia activation. *Behavioural Brain Research, 332*, 145-153. [DOI: 10.1016/j.bbr.2017.05.066]
20. Tsartsalis, S., Panagopoulos, P. K., & Mironidou-Tzouveleki, M. (2011). Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: The use of non-steroidal anti-inflammatory drugs. *CNS & Neurological Disorders Drug Targets, 10*(1), 133-139. [DOI: 10.2174/187152711794488629]